GLP-1s in Oncology: Mixed Evidence and Shared Decision-Making

Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawThe evidence behind a boxed warning for thyroid cancer that has made many oncology clinicians wary of glucagon-like peptide-1 (GLP-1) receptor agonists is weaker than most practitioners realize, while emerging data suggest that these drugs may reduce cancer risk, experts said at HOPA 2026, in New Orleans.Meanwhile, patients are showing up to oncology clinics already on GLP-1s, forcing pharmacists to make real-